Filamin-A expression in triple-negative breast cancer and its clinical significance

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Chen C, Gao D, Huo J, et al. Multiomics analysis reveals CT83 is the most specific gene for triple negative breast cancer and its hypomethylation is oncogenic in breast cancer. Sci Rep. 2021; 11(1):12172.
   PubMed Web of Science ®Google Scholar
• Yin L, Duan JJ, Bian XW, et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22(1):61.
   PubMed Web of Science ®Google Scholar
• Swain S. Triple-negative breast cancer: metastatic risk and role of platinum agents. 2008 ASCO Clinical Science Symposium; 2008 June 3; Chicago, IL, USA.
   Google Scholar
• Blanchard Z, Paul BT, Craft B, et al. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers. Breast Cancer Res. 2015;17:5.
   PubMed Web of Science ®Google Scholar
• Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16(Suppl 1):1–11.
   PubMed Web of Science ®Google Scholar
• Wang K, Ash JF, Singer SJ. Filamin, a new high-molecular-weight protein found in smooth muscle and non-muscle cells. Proc Natl Acad Sci USA. 1975;72(11):4483–4486.
   PubMed Web of Science ®Google Scholar
• Feng Y, Walsh CA. The many faces of filamin: a versatile molecular scaffold for cell motility and signalling. Nat Cell Biol. 2004;6(11):1034–1038.
   PubMed Web of Science ®Google Scholar
• Popowicz GM, Schleicher M, Noegel AA, et al. Filamins: promiscuous organizers of the cytoskeleton. Trends Biochem Sci. 2006;31(7):411–419.
   PubMed Web of Science ®Google Scholar
• Savoy RM, Ghosh PM. The dual role of filamin a in cancer: can’t live with (too much of) it, can’t live without it. Endocr Relat Cancer. 2013;20(6):R341–56.
   PubMed Web of Science ®Google Scholar
• Nallapalli RK, Ibrahim MX, Zhou AX, et al. Targeting filamin a reduces K-RAS-induced lung adenocarcinomas and endothelial response to tumor growth in mice. Mol Cancer. 2012;11:50.
   PubMed Web of Science ®Google Scholar
• Ai J, Huang H, Lv X, et al. FlNA and PGK1 are two potential markers for progression in hepatocellular carcinoma. Cell Physiol Biochem. 2011;27(3–4):207–216.
   PubMedGoogle Scholar
• Lin JF, Xu J, Tian HY, et al. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int J Cancer. 2007;121(12):2596–2605.
   PubMed Web of Science ®Google Scholar
• Zhao P, Ma W, Hu Z, et al. Filamin A (FLNA) modulates chemosensitivity to docetaxel in triple-negative breast cancer through the MAPK/ERK pathway. Tumour Biol. 2016; 37(4):5107–5115.
   PubMedGoogle Scholar
• Tian HM, Liu XH, Han W, et al. Differential expression of filamin a and its clinical significance in breast cancer. Oncol Lett. 2013; 6(3):681–686.
   PubMed Web of Science ®Google Scholar
• Fredolini C, Pathak KV, Paris L, et al. Shotgun proteomics coupled to nanoparticle-based biomarker enrichment reveals a novel panel of extracellular matrix proteins as candidate serum protein biomarkers for early-stage breast cancer detection. Breast Cancer Res. 2020; 22(1):135.
   PubMed Web of Science ®Google Scholar
• Cao W, Jiang Y, Ji X, et al. Identification of novel prognostic genes of triple-negative breast cancer using Meta-analysis and weighted gene co-expressed network analysis. Ann Transl Med. 2021;9(3):205.
   PubMed Web of Science ®Google Scholar
• Zhang D, An X, Yu H, et al. The regulatory effect of 6-TG on lncRNA-miRNA-mRNA ceRNA network in triple-negative breast cancer cell line. Biosci Rep. 2021 41(2):BSR20203890.
   Web of Science ®Google Scholar
• Joshua LM, Huda F, Rao S, et al. Clinicopathological significance of immunohistochemical expression of filamin a in breast cancer. J Carcinog. 2020;19:13.
   PubMedGoogle Scholar
• Jiang X, Yue J, Lu H, et al. Inhibition of filamin-A reduces cancer metastatic potential. Int J Biol Sci. 2013;9(1):67–77.
   PubMed Web of Science ®Google Scholar
• Baccelli I, Stenzinger A, Vogel V, et al. Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. Oncotarget. 2014;5(18):8147–8160.
   PubMedGoogle Scholar
• Li Q, Cao J, He Y, et al. R5, a neutralizing antibody to Robo1, suppresses breast cancer growth and metastasis by inhibiting angiogenesis via down-regulating filamin A. Exp Cell Res. 2020;387(1):111756.
   PubMed Web of Science ®Google Scholar
• Xu Y, Bismar T, Su J, et al. Filamin a regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J Exp Med. 2010;207(11):2421–2437.
   PubMed Web of Science ®Google Scholar
• Guo Y, Li M, Bai G, et al. Filamin a inhibits tumor progression through regulating BRCA1 expression in human breast cancer. Oncol Lett. 2018;16(5):6261–6266.
   PubMed Web of Science ®Google Scholar
• Yue J, Lan S, Yuan C, et al. Prognostic values of Filamin-A status for topoisomerase II poison chemotherapy. Int J Biol Sci. 2012;8(4):442–450.
   PubMed Web of Science ®Google Scholar
• Bedolla RG, Wang Y, Asuncion A, et al. Nuclear versus cytoplasmic localization of filamin a in prostate cancer: immunohistochemical correlation with metastases. Clin Cancer Res. 2009;15(3):788–796.
   PubMed Web of Science ®Google Scholar
• Yue J, Wang Q, Lu H, et al. The cytoskeleton protein filamin-A is required for an efficient recombinational DNA double strand break repair. Cancer Res. 2009;69(20):7978–7985.
   PubMed Web of Science ®Google Scholar
• Meng X, Yuan Y, Maestas A, et al. Recovery from DNA damage-induced G2 arrest requires actin-binding protein filamin-A/actin-binding protein 280 . J Biol Chem. 2004;279(7):6098–6105.
   PubMed Web of Science ®Google Scholar
• Uramoto H, Akyurek LM, Hanagiri T. A positive relationship between filamin and VEGF in patients with lung cancer. Anticancer Res. 2010;30:3939–3944.
   PubMed Web of Science ®Google Scholar
• Ji ZM, Yang LL, Ni J, et al. Silencing filamin a inhibits the invasion and migration of breast cancer cells by up-regulating 14-3-3σ. Curr Med Sci. 2018 38(3):461–466.
   PubMed Web of Science ®Google Scholar
• Phan L, Chou PC, Velazquez-Torres G, et al. The cell cycle regulator 14-3-3σ opposes and reverses cancer metabolic reprogramming. Nat Commun. 2015;6:7530.
   PubMed Web of Science ®Google Scholar
• Collier MEW, Ettelaie C, Goult BT, et al. Investigation of the filamin A-dependent mechanisms of tissue factor incorporation into microvesicles. Thromb Haemost. 2017; 117(11):2034–2044.
   PubMed Web of Science ®Google Scholar
• Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol. 2009;27(29):4834–4838.
   PubMed Web of Science ®Google Scholar
• Kim H, Sengupta A, Glogauer M, et al. Filamin a regulates cell spreading and survival via beta1 integrins. Exp Cell Res. 2008;314(4):834–846.
   PubMed Web of Science ®Google Scholar
• Gehler S, Baldassarre M, Lad Y, et al. Filamin A-beta1 integrin complex tunes epithelial cell response to matrix tension. Mol Biol Cell. 2009;20(14):3224–3238.
   PubMed Web of Science ®Google Scholar
• Leung R, Wang Y, Cuddy K, et al. Filamin a regulates monocyte migration through Rho small GTPases during osteoclastogenesis. J Bone Miner Res. 2010;25(5):1077–1091.
   PubMed Web of Science ®Google Scholar
• Ohta Y, Hartwig JH, Stossel TP. FilGAP, a rho- and ROCK-regulated GAP for Rac binds filamin a to control actin remodelling. Nat Cell Biol. 2006;8(8):803–814.
   PubMed Web of Science ®Google Scholar
• Alper O, Stetler-Stevenson WG, Harris LN, et al. Novel anti-filamin-A antibody detects a secreted variant of filamin-a in plasma from patients with breast carcinoma and high-grade astrocytoma. Cancer Sci. 2009;100(9):1748–1756.
   PubMed Web of Science ®Google Scholar
• Ravid D, Chuderland D, Landsman L, et al. Filamin a is a novel caveolin-1-dependent target in IGF-I-stimulated cancer cell migration. Exp Cell Res. 2008;314(15):2762–2773.
   PubMed Web of Science ®Google Scholar